Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

[Role of radiation therapy in the management of pancreatic cancer].

Huguet F, Rivin Del Campo E, Antoni D, Vendrely V, Hammel P.

Cancer Radiother. 2018 Aug 9. pii: S1278-3218(18)30161-6. doi: 10.1016/j.canrad.2018.06.005. [Epub ahead of print] French.

PMID:
30100126
2.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Perre PV, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Paillerets BB, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D.

Eur J Hum Genet. 2018 Aug 8. doi: 10.1038/s41431-018-0224-1. [Epub ahead of print]

PMID:
30089825
3.

Efficacy and Safety of Sunitinib in Patients With Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke M, Qin SK, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru A, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein P, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan G, Morizane C, Galdy S, Khosravan R, Fernandez K, Rosbrook B, Fazio N.

Neuroendocrinology. 2018 Jul 10. doi: 10.1159/000491999. [Epub ahead of print]

PMID:
29991024
4.

Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process.

Faille D, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Lévy P, Ruszniewski P, Ajzenberg N, Rebours V.

Oncotarget. 2018 May 29;9(41):26453-26465. doi: 10.18632/oncotarget.25458. eCollection 2018 May 29.

5.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer. 2018 May 14. doi: 10.1002/ijc.31603. [Epub ahead of print]

PMID:
29756206
6.

Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors.

Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R.

J Visc Surg. 2018 Apr;155(2):117-125. doi: 10.1016/j.jviscsurg.2017.12.008. Epub 2018 Feb 12.

PMID:
29397338
7.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
8.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12. Review.

9.

Metallic ferromagnetic films with magnetic damping under 1.4 × 10-3.

Lee AJ, Brangham JT, Cheng Y, White SP, Ruane WT, Esser BD, McComb DW, Hammel PC, Yang F.

Nat Commun. 2017 Aug 10;8(1):234. doi: 10.1038/s41467-017-00332-x.

10.

5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours.

de Mestier L, Cros J, Hammel P.

Pancreatology. 2017 Jul - Aug;17(4):527-528. doi: 10.1016/j.pan.2017.06.004. Epub 2017 Jun 8. No abstract available.

PMID:
28619285
11.

Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.

Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):904-908. doi: 10.1097/MEG.0000000000000901.

PMID:
28471829
12.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
13.

Surgery for pancreatic neoplasms: How accurate are our surgical indications?

Birnbaum DJ, Gaujoux S, Berbis J, Dokmak S, Hammel P, Vullierme MP, Lévy P, Sauvanet A.

Surgery. 2017 Jul;162(1):112-119. doi: 10.1016/j.surg.2017.01.015. Epub 2017 Feb 23.

PMID:
28237644
14.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.

15.

Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.

Hammel P, Coriat R, Lledo G, de Bausset M, Selosse M, Obled S, Bonnetain F.

Bull Cancer. 2017 Apr;104(4):321-331. doi: 10.1016/j.bulcan.2016.11.022. Epub 2017 Jan 11.

PMID:
28087054
16.

Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.

Oudard S, Elaidi R, Brizard M, Le Rest C, Caillet V, Deveaux S, Benoit G, Corréas JM, Benoudiba F, David P, Gaudric A, Hammel P, Joly D, Timsit MO, Méjean A, Richard S.

Oncotarget. 2016 Dec 20;7(51):85306-85317. doi: 10.18632/oncotarget.13301.

17.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
18.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
19.

Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply.

Huguet F, Goldstein D, Hammel P.

JAMA. 2016 Oct 4;316(13):1409-1410. doi: 10.1001/jama.2016.9781. No abstract available.

PMID:
27701655
20.

Biodegradable and plasma-treated electrospun scaffolds coated with recombinant Olfactomedin-like 3 for accelerating wound healing and tissue regeneration.

Dunn LL, de Valence S, Tille JC, Hammel P, Walpoth BH, Stocker R, Imhof BA, Miljkovic-Licina M.

Wound Repair Regen. 2016 Nov;24(6):1030-1035. doi: 10.1111/wrr.12485. Epub 2016 Oct 12.

PMID:
27684720
21.

Magnetic resonance force detection using a membrane resonator.

Scozzaro N, Ruchotzke W, Belding A, Cardellino J, Blomberg EC, McCullian BA, Bhallamudi VP, Pelekhov DV, Hammel PC.

J Magn Reson. 2016 Oct;271:15-20. doi: 10.1016/j.jmr.2016.07.012. Epub 2016 Jul 27.

PMID:
27522542
22.

Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.

Endocr Relat Cancer. 2016 Oct;23(10):T57-67. doi: 10.1530/ERC-16-0269. Epub 2016 Aug 10. Review.

23.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F.

Br J Cancer. 2016 Jul 26;115(3):281-9. doi: 10.1038/bjc.2016.212. Epub 2016 Jul 12.

24.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

25.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S.

Acta Oncol. 2016 Sep - Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.

PMID:
27333436
26.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD.

J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.

27.

Electron Paramagnetic Resonance of a Single NV Nanodiamond Attached to an Individual Biomolecule.

Teeling-Smith RM, Jung YW, Scozzaro N, Cardellino J, Rampersaud I, North JA, Šimon M, Bhallamudi VP, Rampersaud A, Johnston-Halperin E, Poirier MG, Hammel PC.

Biophys J. 2016 May 10;110(9):2044-52. doi: 10.1016/j.bpj.2016.03.022.

28.

OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?

Faille D, Ajzenberg N, de Chaisemartin L, Granger V, Chollet-Martin S, de Raucourt E, Hammel P, Lévy P, Ruszniewski P, Rebours V.

Thromb Res. 2016 Apr;140 Suppl 1:S170-1. doi: 10.1016/S0049-3848(16)30123-2. Epub 2016 Apr 8.

PMID:
27161678
29.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group.

JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324.

PMID:
27139057
30.

Nanofiber-based paramagnetic probes for rapid, real-time biomedical oximetry.

Bhallamudi VP, Xue R, Purser CM, Presley KF, Banasavadi-Siddegowda YK, Hwang J, Kaur B, Hammel PC, Poirier MG, Lannutti JJ, Pandian RP.

Biomed Microdevices. 2016 Apr;18(2):38. doi: 10.1007/s10544-016-0063-1.

PMID:
27106026
31.

Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.

Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E.

Nat Rev Clin Oncol. 2016 Sep;13(9):537-49. doi: 10.1038/nrclinonc.2016.37. Epub 2016 Mar 31. Review.

PMID:
27030075
32.

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L.

Clin Transl Gastroenterol. 2016 Mar 24;7:e157. doi: 10.1038/ctg.2016.18.

33.

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, Maire F, Hammel P, Ruszniewski P, Fenaux P.

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1. No abstract available.

34.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

35.

Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.

Cesaretti M, Abdel-Rehim M, Barbier L, Dokmak S, Hammel P, Sauvanet A.

J Visc Surg. 2016 Jun;153(3):173-81. doi: 10.1016/j.jviscsurg.2015.11.014. Epub 2016 Jan 13.

PMID:
26775202
36.

Ferromagnetic Resonance Spin Pumping and Electrical Spin Injection in Silicon-Based Metal-Oxide-Semiconductor Heterostructures.

Pu Y, Odenthal PM, Adur R, Beardsley J, Swartz AG, Pelekhov DV, Flatté ME, Kawakami RK, Pelz J, Hammel PC, Johnston-Halperin E.

Phys Rev Lett. 2015 Dec 11;115(24):246602. doi: 10.1103/PhysRevLett.115.246602. Epub 2015 Dec 10.

PMID:
26705647
38.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group.

BMC Cancer. 2015 Oct 6;15:653. doi: 10.1186/s12885-015-1656-4.

39.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.

Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepère C, Bonnetain F, Taieb J.

Br J Cancer. 2015 Sep 29;113(7):989-95. doi: 10.1038/bjc.2015.328. Epub 2015 Sep 15.

40.

Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.

Bachet JB, Gay F, Maréchal R, Galais MP, Adenis A, MsC DS, Cros J, Demetter P, Svrcek M, Bardier-Dupas A, Emile JF, Hammel P, Ebenezer C, Berlier W, Godfrin Y, André T.

Pancreas. 2015 Oct;44(7):1141-7. doi: 10.1097/MPA.0000000000000394.

PMID:
26355551
41.

Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.

Cros J, Moati E, Raffenne J, Hentic O, Svrcek M, de Mestier L, Sbidian E, Guedj N, Bedossa P, Paradis V, Sauvanet A, Panis Y, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2016;103(5):495-9. doi: 10.1159/000440724. Epub 2015 Sep 4.

PMID:
26335532
42.

State of the art and future directions of pancreatic ductal adenocarcinoma therapy.

Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P.

Pharmacol Ther. 2015 Nov;155:80-104. doi: 10.1016/j.pharmthera.2015.08.006. Epub 2015 Aug 20. Review.

PMID:
26299994
43.

[Pancreatic adenocarcinoma: 10 years of progress].

Hammel P, Neuzillet C, Bendaoud S, Lekhal C, de Mestier L, Hentic O.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S62-71. doi: 10.1016/S0007-4551(15)31219-4. Review. French.

PMID:
26118879
44.

Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.

de Mestier L, Hentic O, Cros J, Walter T, Roquin G, Brixi H, Lombard-Bohas C, Hammel P, Diebold MD, Couvelard A, Ruszniewski P, Cadiot G.

Ann Intern Med. 2015 May 19;162(10):682-9. doi: 10.7326/M14-2132.

PMID:
25984844
45.

Junctional adhesion molecule B interferes with angiogenic VEGF/VEGFR2 signaling.

Meguenani M, Miljkovic-Licina M, Fagiani E, Ropraz P, Hammel P, Aurrand-Lions M, Adams RH, Christofori G, Imhof BA, Garrido-Urbani S.

FASEB J. 2015 Aug;29(8):3411-25. doi: 10.1096/fj.15-270223. Epub 2015 Apr 24.

PMID:
25911611
46.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P.

Ann Oncol. 2015 Jun;26(6):1194-200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9.

47.

High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.

Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bédossa P, Paradis V, Sauvanet A, Bachet JB, Ruszniewski P, Raymond E, Hammel P, Cros J.

Histopathology. 2015 Nov;67(5):664-76. doi: 10.1111/his.12691. Epub 2015 May 12.

PMID:
25809563
48.

Pancreatic neuroendocrine tumors in von Hippel-Lindau disease.

de Mestier L, Hammel P.

Scand J Gastroenterol. 2015 Aug;50(8):1054-5. doi: 10.3109/00365521.2015.1022211. Epub 2015 Mar 2. No abstract available.

PMID:
25731071
49.

Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations.

Sipos B, Sperveslage J, Anlauf M, Hoffmeister M, Henopp T, Buch S, Hampe J, Weber A, Hammel P, Couvelard A, Höbling W, Lieb W, Boehm BO, Klöppel G.

J Clin Endocrinol Metab. 2015 May;100(5):E783-8. doi: 10.1210/jc.2014-4405. Epub 2015 Feb 19.

PMID:
25695890
50.

Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.

Colussi O, Voron T, Pozet A, Hammel P, Sauvanet A, Bachet JB, Vaillant JC, Rougier P, Nordlinger B, Berger A, Coriat R, Dousset B, Malka D, André T, Paye F, Aparicio T, Locher C, Cojean Zeleck D, Tchinou L, Bonnetain F, Taieb J.

Eur J Surg Oncol. 2015 Apr;41(4):520-6. doi: 10.1016/j.ejso.2015.01.010. Epub 2015 Jan 24.

PMID:
25680954

Supplemental Content

Loading ...
Support Center